Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 443 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed722    
    Printed56    
    Emailed1    
    PDF Downloaded221    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 2000  |  Volume : 42  |  Issue : 3  |  Page : 295-301

A Double-Blind, Placebo-Controlled Evaluation of the Anxiolytic Efficacy ff an Ethanolic Extract of Withania Somnifera


1 Additional Professor & Head, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
2 Research Assistant, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
3 Additional Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
4 Chief Consultant, Spandana Psychiatric Hospital, Bangalore-560010, India

Correspondence Address:
Chittaranjan Andrade
Additional Professor & Head, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21407960

Rights and PermissionsRights and Permissions

A double-blind, placebo-controlled study was conducted to evaluate the efficacy an ethanolic extract of Aswagandha (Withania somnifera), in patients with ICD-10 anxiety disorders. The sample comprised 39 subjects, of whom 20 received the drug and 19 received placebo. The two groups were sociodemographically and clinically similar at baseline. At 2 and 6 weeks follow-up, data from approximately 85% of patients in each group were available for analysis. Statistical trends favouring the drug were observed at both time points. At 6 weeks, significantly more patients met a priori response criteria in the drug group (88.2%) as compared with the placebo group (50%). The drug was well-tolerated and did not occasion more adverse effects than did placebo. It is concluded that this ethanolic extract of Withania somnifera has useful anxiolytic potential and merits further investigation.



[PDF]*

        

Print this article         Email this article